Acquired Flucytosine Resistance during Combination Therapy with Caspofungin and Flucytosine for *Candida glabrata* Cystitis

Caroline Charlier, a Carine El Sissy, b Sophie Bachelier-Bassi, c Anne Scemla, d Gilles Quesne, e Emille Sitterlé, b Christophe Legendre, d Olivier Lortholary, a Marie-Elisabeth Bougnoux a,c


Treatment of *Candida glabrata* cystitis remains a therapeutic challenge, and an antifungal combination using flucytosine is one option. We describe two patients with refractory *C. glabrata* cystitis who failed flucytosine combined with caspofungin with early-acquired high-level resistance to flucytosine due to nonsense mutations in the *FUR1* gene. Rapidly acquired flucytosine resistance with microbiological failure should discourage combination of caspofungin and flucytosine during urinary candidiasis.

Candiduria is a therapeutic challenge. Current recommendations mostly rely on fluconazole, and options against intrinsically fluconazole-less-susceptible or -resistant species like *Candida glabrata* are limited (1). Whereas echinocandins exert a high fungicidal effect on *Candida* spp., their use in this setting remains unclear (2). They display poor glomerular filtration and tubular secretion, with only 1% of the drug excreted unchanged, whereas fluconazole and flucytosine achieve high urine concentrations (10 to 100 times the serum levels) (3). Limited observations have, however, reported successful echinocandin-based treatments during candiduria (4). Flucytosine also displays excellent activity against most *Candida* species, except *C. krusei*. High rates of acquired resistance during monotherapy are considered its major limitation and argue for systematic combination therapy, such as that with an azole, amphotericin B, or one echinocandin.

Here, we describe two patients with refractory *C. glabrata* cystitis who received caspofungin and flucytosine with early emergence of high-level flucytosine resistance caused by a stop codon in the *FUR1* gene and microbiological failure.

### Case 1

A 66-year-old woman presented with symptomatic *C. glabrata* cystitis. She had undergone a kidney transplantation 1 month before but had no kidney abscess or urine retention. Blood cultures remained negative. The initial isolate was susceptible to caspofungin and flucytosine with the following MIC values (Etest; bioMérieux, Marcy l’Etoile, France): flucytosine, 178–207 μg/ml; caspofungin, 0.5–1 μg/ml.

### Patient 1

A 66-year-old woman presented with symptomatic *C. glabrata* cystitis. She had undergone a kidney transplantation 1 month before but had no kidney abscess or urine retention. Blood cultures remained negative. The initial isolate was susceptible to caspofungin and flucytosine with the following MIC values (Etest; bioMérieux, Marcy l’Etoile, France): flucytosine, 178–207 μg/ml; caspofungin, 0.5–1 μg/ml.

### Patient 2

A 66-year-old woman presented with symptomatic *C. glabrata* cystitis. She had undergone a kidney transplantation 1 month before but had no kidney abscess or urine retention. Blood cultures remained negative. The initial isolate was susceptible to caspofungin and flucytosine with the following MIC values (Etest; bioMérieux, Marcy l’Etoile, France): flucytosine, 178–207 μg/ml; caspofungin, 0.5–1 μg/ml.

### TABLE 1 Summary of polymorphisms and mutations in the *FUR1* and *FCY2* genes of flucytosine-sensitive and -resistant *Candida glabrata* clinical isolates

<table>
<thead>
<tr>
<th>Patient</th>
<th>Polymorphism or mutation in <em>C. glabrata</em> isolate</th>
<th>Flucytosine sensitive</th>
<th>Flucytosine resistant</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Genotype</td>
<td>Phenotype</td>
<td>Genotype</td>
</tr>
<tr>
<td>1</td>
<td>FUR1</td>
<td>FCY2</td>
<td>Fur1p</td>
</tr>
<tr>
<td>1</td>
<td>A96G</td>
<td>G369C</td>
<td>R32R</td>
</tr>
<tr>
<td></td>
<td>T117C</td>
<td>T468C</td>
<td>S39S</td>
</tr>
<tr>
<td></td>
<td>G178G</td>
<td>A915G</td>
<td>WT</td>
</tr>
<tr>
<td></td>
<td>T355C</td>
<td></td>
<td>L119L</td>
</tr>
<tr>
<td></td>
<td>C370T</td>
<td></td>
<td>L124L</td>
</tr>
<tr>
<td></td>
<td>T528C</td>
<td></td>
<td>D176D</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>FUR1</td>
<td>FCY2</td>
<td>Fur1p</td>
</tr>
<tr>
<td>2</td>
<td>T355C</td>
<td>A693G</td>
<td>L119L</td>
</tr>
<tr>
<td></td>
<td>G368G</td>
<td>C813T</td>
<td>WT</td>
</tr>
<tr>
<td></td>
<td>C370T</td>
<td>G1008A</td>
<td>L124L</td>
</tr>
<tr>
<td></td>
<td>T528C</td>
<td>C1425T</td>
<td>D176D</td>
</tr>
<tr>
<td></td>
<td></td>
<td>T1530A</td>
<td>P510P</td>
</tr>
</tbody>
</table>

* Underlined text indicates nucleic acid changes within *FUR1* and *FCY2* genes compared to the sequences of the reference strain CBS138. Boldface text indicates amino acid changes that occurred as a result of sequence insertion or nucleic acid mutation within the *FUR1* gene. WT, wild type.
0.023 mg/liter; amphotericin B, 0.19 mg/liter; fluconazole, 24 mg/liter; voriconazole, 0.5 mg/liter; and caspofungin, 0.125 mg/liter. Specifically, no colony evocative of a flucytosine-resistant subpopulation was evidenced in the inhibition ellipse of the Etest.

She received caspofungin (70 mg at day 1 and then 50 mg/day) for 3 weeks, and then flucytosine was added (50 mg/kg/day, according to creatinine clearance) for 3 subsequent weeks because of caspofungin monotherapy failure. The flucytosine serum peak concentration at day 10 was within the therapeutic range (49 mg/liter). Treatment was stopped because of persisting symptoms and microbiological failure. The *C. glabrata* isolate collected at day 6 of flucytosine treatment and at treatment completion was resistant to flucytosine (MIC of 32 mg/liter without an increase in the caspofungin MIC).

Strains collected before introduction of flucytosine and at day 6 of flucytosine treatment were sequenced for *FCY1*, *FCY2*, and *FUR1*, encoding, respectively, a cytosine permease, a cytosine deaminase, and a uracil phosphotransferase—three genes often

![Diagram](image_url)
exhibiting mutations leading to flucytosine resistance (5). Sequence analysis of the three genes in the initial wild isolate revealed the presence of a number of silent polymorphisms in FUR1 and FCY2 compared to the reference genome CBS138 (Table 1) (6). The same polymorphisms were found in the resistant strain that further displayed a 29-bp insertion within FUR1, creating a frameshift and a premature Stop codon, yielding a truncated protein (Fig. 1). This insertion is the result of a 29-bp duplication, probably by slippage between two short repeated sequences (Fig. 1) (7). Furthermore, isolates collected before and after flucytosine treatment showed identical multilocus sequence type (MLST) profiles (8).

Case 2. A 65-year-old man presented with C. glabrata cystitis. His history included retroperitoneal fibrosis with obstructive chronic kidney disease requiring a double-J catheter (creatinine clearance, 35 ml/min). He had no kidney/prostatic abscess or urinary retention. Blood cultures were negative. The strain was susceptible to caspofungin and flucytosine, with MIC values (Etest) as follows: flucytosine, 0.047 mg/liter; amphotericin B, 0.25 mg/liter; fluconazole, 64 mg/liter; voriconazole, 1 mg/liter; and caspofungin, 0.06 mg/liter. Here again, no colony evocative of a flucytosine-resistant subpopulation was evidenced in the inhibition ellipse of the Etest. He received caspofungin (150 mg/day, in accordance to the dosage evaluated by Betts et al.) plus flucytosine (50 mg/kg/day according to creatinine clearance) for 4 weeks. The peak flucytosine serum concentration at day 4 was 57 mg/liter (9). Urine culture performed 10 days after antifungal initiation yielded C. glabrata with acquired resistance to flucytosine. The MIC values were as follows: flucytosine, 32 mg/liter; and caspofungin, 0.125 mg/liter. The strain collected before introduction of flucytosine was sequenced as described before and exhibited silent polymorphisms in FUR1 and FCY2 compared to the reference strain (Table 1). The resistant strain displayed the same polymorphisms but had one extra nonsense mutation within FUR1, creating a premature Stop codon and hence giving rise to a truncated protein (Table 1). As observed in case 1, both the strains collected prior to and after flucytosine treatment shared the same specific MLST profile.

Overall, the following important conclusions can be drawn from these observations.

(i) These two patients had no concomitant condition that might have explained treatment failure: there was no upper tract infection or parenchymal abscess, urine obstruction, or fungemia. Both received caspofungin/oral flucytosine at standard or even high doses, and both had flucytosine peak concentrations in the therapeutic range. Treatment failure highlights that caspofungin treatment’s indication so far and never in such a small time interval: previous observations indeed reported acquired resistance 1 to 6 months after the treatment’s initiation (12, 13, 14). Altogether, these two observations advocate against the use of caspofungin and flucytosine combinations for the treatment of C. glabrata cystitis.

ACKNOWLEDGMENTS

C.C., C.E.S., S.-B.-B., G.Q., E.S., A.S., and C.L. declare they have no conflicts of interest. O.L. is a consultant for Gilead Sciences and member of the speaker’s bureau of Astellas, Merck, and Pfizer.

FUNDING INFORMATION

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

REFERENCES


